Patients with advanced bladder cancer with alterations in the FGFR3 gene respond well to investigational drug, TYRA-300 (IMAGE)
European Organisation for Research and Treatment of Cancer
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.